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ABSTRACT
Introduction: The aims of this study were: (1)
to investigate the association of vascular
endothelial growth factor isoform A (VEGF-A)
concentration in the anterior chamber liquid
(ACL) with vascular proliferation in patients
with diabetic retinopathy (DR) who had
undergone surgical treatment for cataract and
neovascular glaucoma; (2) to analyze the
association of VEGF-A level in ACL with the
cataract surgery outcomes.
Materials and Methods: Undiluted aqueous
fluid samples were obtained from 207 eyes of
patients who underwent intraocular surgery,
136 patients with diabetes mellitus (DM) and
22 patients without DM. The ACL samples
were obtained during operation. The VEGF-A
levels were analyzed by enzyme-linked
immunosorbent assay.
Results: The lowest VEGF-A levels were in
diabetic patients without signs of DR
[22.75 pg/mL (10.78; 63.36)]. More severe DR
tended to occur in diabetic patients with higher
VEGF-A levels in ACL. In diabetic patients with
proliferative DR (PDR), VEGF-A levels were
significantly higher [336.6 pg/mL (232.3;
410.74)] than in patients without DR
P\0.0001. In patients with terminal stage of
DR [neovascular glaucoma (NG)], VEGF-A levels
were dramatically higher and attained
1,634.01 pg/mL (610.69; 2657.33). In non-
diabetic patients, VEGF-A levels were 95.07
pg/ml (60.92; 129.22). The best visual acuity
results in post-operative period were observed in
the group of diabetic patients without DR. In
the group of patients with PDR, post-operative
visual acuity [0.26 (0.1; 0.42)] was similar to
visual acuity before operation [0.29 (0.13;
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0.44)]. There was no significant increase in
visual acuity due to cataract surgery. In 52.4%
patients, no complications had occurred by the
end of the follow-up period. In 40% patients,
retinal laser coagulation was performed, and in
7.6% patients NG had developed.
Conclusion: VEGF-A level in ACL increases
with DR progression and may be of prognostic
value in evaluating the potential risk of further
neovascularization progression in diabetic
patients.
Keywords: Cataract; Cataract surgery; Diabetes
mellitus; Diabetic retinopathy; Ophthalmology;
Vascular endothelial growth factor
INTRODUCTION
Ophthalmological complications of diabetes
mellitus (DM) remain a major public health
problem. Despite a significant progress in
investigating the causes of diabetic retinopathy
(DR) and the development of therapeutic
methods, DR remains to be a leading cause of
blindness among young persons suffering from
DM; among working-age adults, it causes a
dramatic loss in visual acuity in 5% of cases [1].
DR is caused by chronic hyperglycemia which
results in the activation of the sorbitol shunt,
oxidative damages, accumulation of end-
products of glycation, microcirculation
impairment, hypercoagulation, increased
vascular permeability, endothelial dysfunction,
activation of apoptosis, etc. [2, 3]. Multicenter
clinical trials have shown the efficacy of
preventive measures aimed primarily at good
glycemic control, which permit to achieve 75%
reduction in the risk of visual loss [4]. However,
once DR has developed it usually cannot be
reversed. Accumulation of pathobiochemical and
pathophysiological changes resulting in retinal
damages, its hypoperfusion and ischemia, which
ultimately trigger the production of cytokines
and growth factors [5–7]. A key growth factor
mediating vascular permeability and
neovascularization is a vascular endothelial
growth factor (VEGF), isoform A of which is the
most active and exerts many effects [8]. Retinal
cells (retinal pigment epithelium, pericytes, and
astrocytes) are those which, in response to
hypoxic damage, actively produce VEGF [9–11]
which, in turn, causes its edema and
neovascularization. Eye structures of patients
with DM and DR have been shown to contain
higher amounts of VEGF [12], the levels of which
are decreased following retinal laser coagulation
(RLC) [13].
Nowadays, anti-VEGF agent widely used for
the treatment of DR as well as the age-related
macular degeneration [14, 15], it demonstrated
reducing the macular edema and blockage new
vessels grow. On the other hand, VEGF mediates
normal physiological processes (reparation and
wound healing, ensuring cell survival, normal
course of pregnancy, glomerulogenesis,
vasodilatation, etc.,), the suppression of which
may result in serious adverse reactions in
patients with DM in particular.
The aims of this study were: (1) to investigate
the association of VEGF-A concentration in the
anterior chamber liquid (ACL) with vascular
proliferation in patients with DR who had
undergone surgical treatment for cataract and
neovascular glaucoma; (2) to analyze the
association of VEGF-A level in ACL with the
cataract surgery outcomes.
MATERIALS AND METHODS
This study was a cross-sectional study
evaluating the levels of VEGF-A and glucose in
ACL of DM patients with cataract and
neovascular glaucoma (NG), with a 12-month
follow-up period after cataract extraction.
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From 2007 to 2009, at the Department of
Diabetic Retinopathy and Eye Surgery, 120 DM
patients were operated on for cataract and 16
DM patients with NG were operated for non-
controlled pain glaucoma by valve
implantation. The control group included 22
non-diabetic patients operated on for age-
related cataract.
The patients over 16 years old who had
signed the informed consent form were
included in the study. Exclusion criteria were
previous vitreous, retinal or glaucoma surgery,
eye infections, age-macular degeneration,
chorio-retinal neovascularization, chronic or
immune uveitis, systemic immune-suppressing
therapy.
For all patients, the levels of VEGF-A and
glucose were measured in ACL, which was
collected at baseline (before surgery). The
samples were centrifuged, separated from the
precipitate and stored at -80 C. The levels of
VEGF-A were measured by the enzyme-linked
immunosorbent assay (ELISA) and the glucose
levels by a glucose oxidation method. Patients
were examined before surgery, the day after
surgery and 1, 3, 6, and 12 months after surgery.
To assess the long-term visual outcomes,
the patients were monitored for 12 months
after surgery. At examination performed
immediately after cataract extraction (on next
day), DM patients were assigned to the groups
according to the verified stage of DR. The stage
of DR was determined according to World
Health Organization (WHO) classification [16]:
non-proliferative (NPDR), pre-proliferative
(PPDR), and proliferative (PDR) (Table 1).
Ophthalmic examination included best-
corrected visual acuity (estimation of visual
acuity was performed using the Golovin–
Sivtsev table from a 5-m distance), intraocular
pressure, biomicroscopy, ophthalmoscopy,
ultrasound B-scan, perimetry, and color fundus
photography. For assessment, the diabetes
condition glycated hemoglobin (HbA1C), blood
glucose, blood pressure, microalbuminuria, and
glomerular filtration rate (GFR) were measured.
After the end of the follow-up period, DR
stage and visual acuity were assessed and all
complications were registered.
Statistical Analysis
The descriptive statistics are presented as
median (25th percentile; 75th percentile) as
well as weight percentage (%) for the prevalence
parameters. Visual acuity data are presented as
median (95% CI). To compare more than two
independent groups, Kruskal–Wallis test was
used; then pairwise comparisons using Mann–
Whitney test with the Bonferroni adjustment
was performed. Qualitative data were compared
and contingency tables evaluated using Chi-
square test. The dependent groups were
compared using Wilcoxon test. Correlation
analysis was performed using Spearman’s rank
test (R). To identify the risk factors in the
follow-up groups at the completion of the
prospective phase, risk (IR), risk difference
(RD), relative risk (RR), and odds ratio (OR)
with regard to the occurrence of an endpoint
were calculated using the contingency tables.
Kaplan–Meier survival curve was displayed
based on the prospective follow-up data, and
the significance of the difference was analyzed
using a Cox proportional hazards regression
model.
The critical significance level (P) for
statistical hypothesis testing was set at \0.05.
The study protocol was approved by local
ethics committee and was conducted in
accordance with the guidelines of the Helsinki
Declaration of 1975, as revised in 2000.
Informed consent was obtained from all
patients for being included in the study.
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RESULTS
The cohort comprised 120 patients operated
from cataract: 19 had DM type 1 [age, 51 (31;
59); DM duration, 15 (8; 35); average HbA1C,
8.6% (7.5; 10.6)] and 101 had DM type 2 [age,
70 (64; 73); DM duration, 14 (10; 20), average
HbA1C, 7.9% (6.9; 8.8)]. There were 16 patients
with DM and uncontrolled NG, operated due to
high intraocular pressure [age, 60 (53; 67); DM
duration, 12.5 (6.5; 20.5), average HbA1C, 7.7%
(7.4; 8.9)]. 22 patients without diabetes, which
operated from age-related cataract, were
72 years old (65; 78). The baseline best-
corrected visual acuity was 0.24 (0.14; 0.33) in
patients with DM type 1, 0.23 (0.19; 0.27) in
patients with DM type 2, and 0.24 (0.13; 0.36)
in patients without DM.
The prevalence of DR among the operated
DM patients with cataract is shown in Fig. 1.
Post-operative examination (5–7 days after
operation) has shown that no signs of DR were
present in 8.2% of patients, and NPDR, PPDR,
and PDR were present in 37.2%, 38.2%, and
16.4% of patients, respectively. The likelihood
of PDR detection post-operation was higher by
4.5%. It should also be noted that before
operation PDR was correctly diagnosed in 50%
cases only because of lens opacity interfered the
adequate fundus examination.
Glucose Levels in ACL
On the day of surgery, ACL glucose levels and
fasting plasma glucose were similar in different
groups of DM patients. However, the median
of ACL glucose levels was slightly increased
in the groups with severe forms of DR (from
3.08 in patients without DR to 4.85 in DM
patients with neovascular glaucoma). A direct
relationship exists between ACL glucose
levels and fasting plasma glucose (R = 0.49,
P\0.001), Table 1. HbA1C levels in the
different groups of diabetic patients were also
similar, except for the group of patients without
DR (P\0.001) (in this group, DM was
compensated to the highest possible degree as
the patients had the lowest glucose levels both
in blood and in ACL).
VEGF-A Levels in ACL
VEGF-A levels in ACL of diabetic patients were
increased in the groups with more severe stages of
DR. The lowest VEGF-A levels in ACL were seen in
diabetic patients without signs of DR [22.75
pg/mL (10.78; 63.36)]; they were even lower
than those in the control group [95.07 pg/mL
Fig. 1 Distribution of operated diabetic patients with
cataract according to DR type [examinations have been
performed before (a) and after surgery (b)]. No DR no
signs of diabetic retinopathy were detected, NPDR non-
proliferative diabetic retinopathy, PPDR pre-proliferative
diabetic retinopathy, PDR proliferative diabetic
retinopathy
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(60.92; 129.22)], and the difference was
significant (P = 0.008). In the groups of patients
with a more severe stage of DR, VEGF-A levels in
ACL were higher, with 52.5 pg/mL (44.52; 88.95)
in patients with NPDR and 75.84 pg/mL (71.7;
123.58) in those with PPDR (the difference with a
group of patients without DR was significant,
P = 0.007). In patients with PDR, VEGF-A levels
in ACL attained the highest values [336.6 pg/mL
(232.3; 410.74); P\0.0001]. Therefore, in
diabetic patients with PDR, VEGF-A levels in
ACL were three times higher than those in
control groups and 15 times higher than those
in diabetic patients without DR (Fig. 2). Of
interest, VEGF-A levels in ACL continue to
increase with further DR progression. Indeed, in
diabetic patients with NG (terminal stage of DR)
these levels attained 1,634.01 pg/mL (610.69;
2657.33) and were 4.8 times higher than in
diabetic patients with PDR and 17 times higher
than in the control group (differences with all
groups were significant, P\0.05).
Correlation analysis has shown association
between VEGF-A levels and DR severity
(R = 0.59, P\0.001). However, no correlations
have been found between VEGF-A levels in ACL
and the level of HbA1C, GFR, blood pressure.
Visual Function in Patients with Cataract
Visual function assessments in operated
diabetic patients with cataract on the next
day, at 5th–7th day and at 1st, 3rd, 6th, and
12th month after surgery in the post-operative
period have shown that the best results were
achieved in the groups of patients with less
severe stages of DR (P\0.001). Pre-operative
visual acuity in groups of patients with different
DR stage was similar (P = 0.31). This fact could
be explained by the significant influence of lens
opacity on visual acuity. The majority of
patients had the hard, progressive, cortical or
posterior subcapsular cataract. In groups of
diabetic patients without DR, with NPDR and
with PPDR, visual acuity was significantly
increased post-operation and maintained at
high level over 12 months (P\0.05). However,
in patients with severe stages of DR, visual
acuity in the delayed post-operative period
gradually decreased and returned to baseline
values at 12 months after operation (Fig. 3).
Analysis of Cataract Surgery Outcomes
There is an ongoing discussion on the high-risk
of complications after cataract surgery in
diabetic patients. Therefore, the authors
followed the patients operated for cataract for
12 months after surgery by measuring visual
acuity, assessing DR stage, and monitoring the
complications. Kaplan–Meier survival curve was
displayed based on data obtained in the
observation period: follow-up outcomes were a
decrease in the visual acuity by more than 0.2,
vision loss and development of NG (or rubeosis
iridis). Patients treated with RLC (who
Fig. 2 Median of VEGF-A levels in ACL in operated
patients (pg/mL) as function of DR severity. Axis Y,
VEGF-A in ACL. ACL anterior chamber liquid, DM
diabetes mellitus, DR diabetic retinopathy, NPDR non-
proliferative diabetic retinopathy, PPDR pre-proliferative
diabetic retinopathy, PDR proliferative diabetic retinopa-
thy, NG neovascular glaucoma, VEGF-A vascular endo-
thelial growth factor A
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maintained their visual acuity), patients lost to
follow-up, and patients who required eye
surgery for other indications (different from
follow-up outcomes) were not censored (i.e.,
not taken into account as patients with vision
loss). As seen in Fig. 4, the incidence of vision
loss was higher in patients with high baseline
VEGF-A levels in ACL. The highest incidence of
these episodes was observed from month 3 to 5.
In diabetic patients with the highest VEGF-A
levels in ACL (25% of all patients from the
upper quartile, corresponding to patients with
VEGF-A levels in ACL [137.4 pg/mL), vision
loss at 12 months was observed in 25% of cases,
while in patients with VEGF-A levels in ACL
\137.4 pg/mL, only in 8–9% of cases. As was
shown using a Cox proportional hazards
regression model, these differences were
statistically significant (P = 0.016).
In the overall follow-up group, 7.6% of
patients developed NG by 12 months after
surgery, 40% patients were treated with RLC
due to severe forms of DR, and only 52.4% of
patients had no complications during the post-
operative period.
To evaluate the risks of NG development
in diabetic patients after cataract surgery, the
authors performed a variance analysis assessing
each factor’s contribution (Table 2). The whole
population was divided according to the
presence of the factor studied, and the risk
parameters were calculated for each factor.
Patients with high VEGF-A levels in ACL
([137.4 pg/mL) had a RR with regard to NG
development of 9.62 and OR of 12.3, i.e., the
Fig. 3 Visual acuity changes in patients operated for
cataract. DM diabetes mellitus, DR diabetic retinopathy,
NPDR non-proliferative diabetic retinopathy, PPDR pre-
proliferative diabetic retinopathy, PDR proliferative dia-
betic retinopathy, NG neovascular glaucoma. *P\0.001—
the signiﬁcance of the differences between baseline visual
acuity and visual acuity at 12 months after surgery
(Wilcoxon test). **P\0.05—the signiﬁcance of the
differences of the visual acuity at 12 months between
groups (Mann–Whitney test with the Bonferroni adjust-
ment). The authors checked the best-corrected visual
acuity by the Golovin–Sivtsev table from a 5-m distance. It
had been estimated in conventional units. For example,
visual acuity 1.0 (Golovin–Sivtsev table) is equivalent to
20/20 (Snellen chart); visual acuity 0.1 (Golovin–Sivtsev
table) is equivalent to 20/200 (Snellen chart)
Fig. 4 Percentages of diabetic patients with different
VEGF-A ACL levels in whom visual acuity at 12 months
were maintained at the same level as post-operation. ACL
anterior chamber liquid, VEGF-A vascular endothelial
growth factor A
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risk of NG development in the post-operative
period was 9.62–12.3 higher in these patients
than in the others (the differences were
statistically significant, P = 0.0004). Patients
with low GFR (\60 mL/min) had 5.9–7 times
higher risk than those who had GFR higher
than 60 mL/min (P = 0.009). Other risk factors
(such as, the presence of concurrent open-angle
glaucoma, history of RLC, HbA1C higher than
7.5%, marked hypertension, the presence of
microalbuminuria or proteinuria) also increased
the risk of NG development by 1.65–3.5 times;
however, the differences did not reach
statistical significance P[0.05.
DISCUSSION
Concomitant presence of DR and cataract
worsens the visual prognosis in diabetic
patients and makes it difficult to perform
therapeutic interventions. This study has
shown that lenticular opacities prevent
accurate and prompt verification of DR stage,
with PDR being accurately verified in 50% of
cases only.
Hyperglycemia is clearly a trigger for DR
development and, combined with other
pathophysiological mechanisms, results in
progression of retinopathy. In this study, the
authors have not found any differences in ACL
glucose levels, glycemia, and HbA1C in patients
with different DR stages, except for diabetic
patients without DR in whom ACL glucose
values and HbA1C were at the lowest levels
(differences in HbA1C were statistically
significant). This may be explained by the fact
that good metabolic control prevents the
occurrence of DR signs, however, if DR has
already developed, the markers of carbohydrate
metabolism do not correlate well with the
severity of DR anymore. Because the cause of
the retina neovascularization is the severe
ischemia the use of some medicines (statins,
antiplatelets) should be investigated carefully.
At the same time, VEGF-A levels in ACL
reflected the severity of DR. These levels were
significantly different in various groups of
diabetic patients. VEGF-A levels in ACL
increased with DR progression; the values
achieved were 16-fold higher than in patients
without DM and 65-fold higher than in diabetic
patients without DR. Similar results were shown
in previous studies [17–21], which found
the elevation the vitreous and aqueous
Table 2 Estimated values of risk (IR), risk difference (RD), relative risk (RR), and odds ratio (OR) for the occurrence of
NG in diabetic patients operated for cataract
Variable IR NG (%) RDNG (%) RRNG ORNG v
2
NG (P value)
VEGF-A[137.4 pg/mL 25 22.4 9.62 12.3 0.0004
HbA1C[7.5% 8.3 5.9 3.5 4.8 0.12
Presence of open-angle glaucoma 17.6 11.9 3.09 3.6 0.09
History of RLC 10.7 4.2 1.65 1.6 0.58
Stage II or III hypertension 9.1 4.1 1.82 1.8 0.58
Microalbuminuria/proteinuria 12.8 8.3 2.8 3.1 0.12
GFR\60 mL/min 17 14.1 5.9 7.0 0.009
NG neovascular glaucoma, VEGF-A vascular endothelial growth factor A, NG neovascular glaucoma, HbA1C glycated
hemoglobin, RLC retinal laser coagulation, GFR glomerular ﬁltration rate
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concentration of VEGF in patients with DR. It
proved the essential role of the VEGF in the DR
development and neovascularization of the
retina. PDR is associated with higher level of
the VEGF in the ACL than NPDR. Moreover, NG
due to PDR is associated with extremely high
VEGF level. Several authors [22, 23]
demonstrated the elevation VEGF value in the
glaucomatous eyes and the benefits of the
blockage of the VEGF in the eye [24, 25]. In
this way, VEGF-A levels in ACL are associated
with the severity of DR.
In the current study, cataract surgery and
intraocular lens implantation enhanced the
visual acuity in diabetic patients, but during
follow-up final vision dramatically deteriorated
in patients with PDR. Because the patients of
this group had the highest HbA1C level, long
DM duration about 16 years, more than half of
them treated by panretinal RLC and high
prevalence of the comorbid diseases, all these
factors and high level of the VEGF-A can lead to
progressive visual impairment. According to the
results of this study, during 12-month follow-up
for the operated diabetic patients the authors
found an increase in the RR and OR with regard
to complications due to DR progression in the
groups of patients with high levels of VEGF-A
(the upper quartile for the whole population
studied, i.e.[137.4 pg/mL). Therefore, RR of NG
development (and rubeosis iridis) following
cataract extraction was 9.62, and OR was 12.3.
This implies the high prognostic value of VEGF-
A levels [137.4 pg/mL in evaluating the risk of
complications and their onset times. Similar
results were reported by Wakabayashi et al. [25].
They assessed the vitreous and ACL level
of VEGF as a significant risk factor for the
early post-operative hemorrhage and NVG
development. Thus,medical approaches aimed
to VEGF blockage may be helpful before cataract
surgery among the diabetic patients with high-
risk of NG development. For example in
their study, Grover et al. [26] and Chalam
et al. [27] demonstrated the effectiveness
of the intracameral injection of the
ranibizumab or bevacizumab in reversing iris
neovascularization and decreasing intraocular
pressure in cases of the NG. It was shown that
intravitreal bevacizumab at the time of surgery
was beneficial in reducing central macular
thickness in short term [28–30]. Panretinal
RLC also decreased ocular VEGF concentration
and can prevent DR progression after
phacoemulsification [31, 32].
In the present study, the authors aimed to
find other risk factors which could be evaluated
before surgery for better visual outcomes in
diabetic patients. The authors revealed that
decreasing of the GFR less than 60 mL/min,
significantly increased the risk of NG
development in post-operative period (by
5.9–7.0 times). It can be explained by
expanded circulation of the waist product and,
therefore, more severe retina hypoxia which
resulted to the neo-vessels formation. There
have been a number of studies [33, 34] aimed at
investigating the relationship between DR stage
and renal function which resulted in conflicting
data. The authors used the surrogate markers of
the renal insufficiency (albuminuria and
estimated GFR) and DR (microaneurysms
quantity). The current study showed that the
intraocular VEGF as a direct marker of DR and
cut-off limit of the GFR less than 60 mL/min
correlated with visual outcomes and
significantly increased neovascularization.
Most diabetic patients have many
comorbidities, and the efficacy of treatment is
often decreased. The literature suggests the
increased frequency of complications in diabetic
patients. Therefore, these patients should be
closely monitored for the development of
adverse events, maximum compensation of
Ophthalmol Ther (2013) 2:41–51 49
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diabetes, main metabolic variables, and
concurrent illnesses.
CONCLUSION
VEGF-A clearly plays a key role in the
development and progression of DR, and this
study has shown that its content in ACL increases
with DR progression. On the other hand, VEGF-A
may be of prognostic value in evaluating the
potential risk of further neovascularization
progression in diabetic patients.
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